Initial Experiences of Intravesical Gemcitabine Instillation Followed by Bacillus Calmette-Guerin(BCG) Therapy for Treating Intermediate or High Risk Patients with Superficial Bladder Cancer.
10.4111/kju.2008.49.4.313
- Author:
Jong Wook KIM
1
;
Dae Yeon CHO
;
Jeong Kyun YEO
;
Hong Seok PARK
;
Duck Ki YOON
Author Information
1. Department of Urology, College of Medicine, Korea University, Seoul, Korea. dkyoon@korea.ac.kr
- Publication Type:Original Article
- Keywords:
Gemcitabine;
Bladder cancer;
Intravesical instillation
- MeSH:
Administration, Intravesical;
Bacillus;
Deoxycytidine;
Humans;
Mycobacterium bovis;
Prospective Studies;
Recurrence;
Urinary Bladder;
Urinary Bladder Neoplasms
- From:Korean Journal of Urology
2008;49(4):313-319
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To investigate the safety and the efficacy of intravesical gemcitabine therapy, we prospectively studied intravesical gemcitabine instillation followed by Bacillus Calmette-Guerin(BCG) instillation for treating the patients who suffer from superficial bladder cancer, and the above method was then compared with conventional BCG instillation. MATERIALS AND METHODS: Between May 2005 and April 2007, a total of 84 patients were divided into Group I: the patients were treated with a 2-week course of gemcitabine(1,000mg/50ml, 2,000mg/50ml) followed by a conventional 6-week course of BCG, and Group II: the patients were treated by BCG instillation only. Gemcitabine was instilled immediately within 6 hours after complete trans-urethral resection of the bladder tumor (TURBT) and then this was repeated one week later. BCG instillation was started 2 weeks after TURBT. The complications, recurrence rates, progression rates and recurrence-free period(RFP) were analyzed in both groups. RESULTS: The treatment was well tolerated in all the patients. Most of the complications were self-limiting, and there was no significant difference between the two groups(p=0.379). The recurrence rates of the two groups were 25.6% and 26.7%, respectively(p=0.899). Yet the recurrence-free period(RFP) was significantly longer in Group I(p=0.021). The progression rates of the two groups were 2.6% and 6.7%, respectively(p=0.620). CONCLUSIONS: Intravesical gemcitabine instillation showed the effect to prolong the recurrence-free period for patients with superficial bladder cancer. Further long-term study will be needed.
